Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
Open Access
- 4 June 2019
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X), 1-5
- https://doi.org/10.14218/jcth.2019.00014
Abstract
Background and Aims: Hepatitis C virus (HCV)-infected organs are underutilized. We aimed to assess the safety and efficacy of direct-acting antiviral agents (DAAs) therapy in HCV viremic patients who are transplanted with a liver from a HCV viremic donor.Keywords
This publication has 28 references indexed in Scilit:
- OPTN/SRTR 2015 Annual Data Report: LiverAmerican Journal of Transplantation, 2017
- Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to TherapyJournal of Clinical and Translational Hepatology, 2016
- Management of Post-Liver Transplant Recurrence of Hepatitis CDrugs, 2016
- Changes in Utilization and Discard of Hepatitis C–Infected Donor Livers in the Recent EraAmerican Journal of Transplantation, 2016
- New perspectives for preventing hepatitis C virus liver graft infectionThe Lancet Infectious Diseases, 2016
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusJournal of Hepatology, 2015
- A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapyJournal of Hepatology, 2014
- Interferon free therapy with direct acting antivirals for HCVLiver International, 2013
- Liver Transplantation and Hepatitis CInternational Journal of Hepatology, 2012
- Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysisTransplant International, 2010